

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACTAVIS, INC., ACTAVIS LABORATORIES FL, INC.,
ACTAVIS PHARMA, INC., AMNEAL PHARMACEUTICALS, LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC.,
BRECKENRIDGE PHARMACEUTICAL, INC., VENNOOT
PHARMACEUTICALS, LLC, SANDOZ INC., SUN PHARMA GLOBAL
FZE, and SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Petitioners

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner

Case: IPR2014-01126

**DECLARATION OF CLAYTON H. HEATHCOCK, PH.D.
IN SUPPORT OF PETITION FOR *INTER*
PARTES REVIEW OF U.S. PATENT NO. RE 38,551**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450
Submitted Electronically via the Patent Review Processing System

EXHIBIT
ACTAVIS, AMNEAL,
AUROBINDO,
BRECKENRIDGE,
VENNOOT,
SANDOZ, SUN
IPR2014-01126-1002 p. 1

TABLE OF CONTENTS

Exhibits Referenced In This Declaration	iv
I. INTRODUCTION AND QUALIFICATIONS	1
A. Educational Background	1
B. Career History and Relevant Industry Participation	2
II. SCOPE OF ASSIGNMENT AND COMPENSATION.....	5
III. LEGAL PRINCIPLES USED IN MY ANALYSIS.....	6
A. Person of Ordinary Skill in the Art	6
B. Prior Art.....	7
C. Anticipation	8
D. Obviousness.....	9
IV. SUMMARY OF MY OPINIONS	10
V. THE '551 PATENT.....	11
A. Overview of the '551 Patent – The Alleged Invention	11
B. Overview of Claims 1-13 of the '551 Patent	11
C. Claim Construction of the '551 Patent.....	14
VI. TECHNICAL BACKGROUND	15
A. Representation of Chemical Structures	15
B. Amino Acids.....	19
C. Stereochemistry	21
D. Background on Drug Development	27
VII. CLAIMS 1-13 OF THE '551 PATENT ARE ANTICIPATED BY THE '301 PATENT.....	28

A.	The '301 Patent Discloses Lacosamide.....	29
B.	The Preferences Disclosed by the '301 Patent Lead Directly to One Compound—Lacosamide—in Claim 44	32
C.	Claims 1-9 of the '551 Patent are Anticipated by the '301 Patent.....	34
D.	Claim 10 of the '551 Patent is Anticipated by the '301 Patent.....	36
E.	Claims 11-13 of the '551 Patent are Anticipated by the '301 Patent	37
VIII.	CLAIMS 1-13 OF THE '551 PATENT ARE ANTICIPATED BY THE LEGALL THESIS	38
A.	The LeGall Thesis Discloses Racemic Lacosamide as an Anticonvulsant Compound.....	39
B.	A POSA was Enabled by the LeGall Thesis and the Prior Art to Isolate the R Enantiomer, Lacosamide, in Pure Form	42
C.	Claims 1-9 of the '551 Patent are Anticipated by the LeGall Thesis.....	46
D.	Claim 10 of the '551 Patent is Anticipated by the LeGall Thesis	47
E.	Claims 11-13 of the '551 Patent are Anticipated by the LeGall Thesis.....	48
IX.	CLAIMS 1-13 OF THE '551 PATENT ARE OBVIOUS	49
A.	The Scope and Content of the Prior Art.....	50
1.	Structure-Activity Relationships Were Well-Known For The Class Of Compounds Covered By The '551 Patent	50
2.	The Substitution of Methyl for Amino Groups was Commonly Performed in the Prior Art	78
3.	The Prior Art Taught The Preparation Of Enantiomerically Pure D-Serine And Its Derivatives	80
B.	The Differences Between the Prior Art and Claims	83

1.	Claims 1 and 3-8 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....	83
2.	Claims 2 and 9 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....	96
3.	Claim 10 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art.....	99
4.	Claims 11-13 of the '551 Patent Would Have Been Obvious in View of the LeGall Thesis and Other Prior Art...	102
C.	The Level of Ordinary Skill in the Art.....	109
D.	Secondary Considerations or Objective Indicia of Nonobviousness.....	109
X.	CONCLUSION.....	109

EXHIBITS REFERENCED IN THIS DECLARATION

Exhibit	Description
1001	U.S. Patent No. RE 38,551 to Kohn (“’551 patent”) (reissue of U.S. Patent No. 5,773,475 (“’475 patent”))
1003	U.S. Patent No. 5,654,301 to Kohn and Watson (the “’301 patent”)
1004	Jan. 28, 1998 Notice of Allowability (excerpt from prosecution history of ’475 patent)
1005	Philippe LeGall, <i>2-Substituted-2-acetamido-N-benzylacetamides. Synthesis, Spectroscopic and Anticonvulsant Properties</i> (Dec. 1987) (“LeGall thesis”)
1006	Apr. 10, 1998 Amendment Under 37 C.F.R. § 1.312 (excerpt from prosecution history of ’475 patent)
1008	U.S. Patent No. 5,378,729 to Kohn and Watson (“’729 patent”)
1009	Sergio Cortes et al., <i>Effect of Structural Modification of the Hydantoin Ring on Anticonvulsant Activity</i> , 28 J. Med. Chem. 601 (1985) (“Cortes”)
1010	Harold Kohn et al., <i>Preparation and Anticonvulsant Activity of a Series of Functionalized α-Heteroatom-Substituted Amino Acids</i> , 34 J. Med. Chem. 2444 (1991) (“Kohn 1991”)
1012	U.S. Provisional Patent Application No. 60/013,522 (“’522 prov. app.”)
1014	Phillipe LeGall et al., <i>Synthesis of Functionalized Non-Natural Amino Acid Derivatives via Amidoalkylation Transformations</i> , 32 Int’l J. Peptide Protein Res. 279 (1988) (“LeGall 1988”)
1015	R. L. M. Syngé, <i>CCXXXIX. Experiments On Amino Acids. IV. The Methyl Ethers Of Some N-Acetyl-Hydroxyamino-</i>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.